Shareholder Alert: Robbins LLP Informs Investors of the Apple, Inc. Class Action Lawsuit

Shareholder Alert: Robbins LLP Informs Investors of the Apple, Inc. Class Action Lawsuit GlobeNewswire July 03, 2025 SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) — Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or acquired Apple, Inc. (NASDAQ: AAPL) securities between June 10, 2024 and June […]

Petco Health and Wellness Company, Inc. Class Action Notice: Robbins LLP Reminds WOOF Investor of the Lead Plaintiff Deadline in the WOOF Class Action Lawsuit

(NASDAQ:WOOF), SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) securities between January 14, 2021 and June 5, 2025. Petco is a specialty retailer that offers a variety of

Petco Health and Wellness Company, Inc. Class Action Notice: Robbins LLP Reminds WOOF Investor of the Lead Plaintiff Deadline in the WOOF Class Action Lawsuit

Petco Health and Wellness Company, Inc. Class Action Notice: Robbins LLP Reminds WOOF Investor of the Lead Plaintiff Deadline in the WOOF Class Action Lawsuit GlobeNewswire July 03, 2025 SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise

Sarepta Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds SRPT Stockholders of the Lead Plaintiff Deadline in the SRPT Class Action Lawsuit

(NASDAQ:SRPT), SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025. Sarepta is a commercial-stage biopharmaceutical company that focuses on RNA and gene therapies

Sarepta Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds SRPT Stockholders of the Lead Plaintiff Deadline in the SRPT Class Action Lawsuit

Sarepta Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds SRPT Stockholders of the Lead Plaintiff Deadline in the SRPT Class Action Lawsuit GlobeNewswire July 03, 2025 SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics,

Midwest’s Biggest Digital Learning Event is Happening in Kansas City

A “Must Attend” for Potential Homeschoolers Accredited schools and leading curriculum providers from across the country are visiting Kansas City for Acellus World, a family-fun educational extravaganza. Taking place July 10-12 from 9:00 AM to 10:00 PM at the new Acellus Conference Center, Acellus World aims to be the largest digital learning event in the

Aura Announces Preliminary Q2 2025 Production Results

(TSX:ORA),(Bovespa:AURA33.SA),(OTC US:ORAAF),(Other OTC:ORAAF),(Bovespa:AURA33), ROAD TOWN, British Virgin Islands, July 03, 2025 (GLOBE NEWSWIRE) — Aura Minerals Inc. (TSX: ORA, B3: AURA33 and OTCQX: ORAAF) (“Aura” or the “Company”) is pleased to announce Q2 2025 preliminary production results from the Company's operating mines: Aranzazu, Apoena, Minosa, Almas and Borborema. Total production in Q2 2025 reached 64,033

Aura Announces Preliminary Q2 2025 Production Results

Aura Announces Preliminary Q2 2025 Production Results GlobeNewswire July 03, 2025 ROAD TOWN, British Virgin Islands, July 03, 2025 (GLOBE NEWSWIRE) — Aura Minerals Inc. (TSX: ORA, B3: AURA33 and OTCQX: ORAAF) (“Aura” or the “Company”) is pleased to announce Q2 2025 preliminary production results from the Company's operating mines: Aranzazu, Apoena, Minosa, Almas and

Remote Pharmacy Releases 2025 Availability Update on GLP-1 Weight Loss Solutions and Consumer Interest in Semaglutide & Tirzepatide

Bowling Green, July 03, 2025 (GLOBE NEWSWIRE) — Section 1 – Introduction In 2025, the discourse surrounding prescription weight loss treatments is gaining momentum, fueled by increasing public awareness of GLP-1 receptor agonists, such as semaglutide and tirzepatide. Developed initially as antidiabetic agents, these medications are now at the forefront of interest in physician-monitored, non-surgical

Scroll to Top